Perspective

Remdesivir, Favipiravir and Dexamethasone Linked to SARS CoV-2 Variants of Interest and Concern: Could Molnupiravir and SARS CoV-2 Mass Vaccination Programs Add Oil to The Fire?

Mina T. Kelleni, MD, PhD

Pharmacology Department, College of Medicine, Minia University, Egypt

mina.kelleni@mu.edu.eg; drthabetpharm@yahoo.com

Mobile: +201200382422

<https://orcid.org/0000-0001-6290-6025>

Competing interests

None

Funding

None

Abstract

SARS CoV-2 Variants of interest and concern are considered a real challenge to our medical efforts to stem down COVID-19. We suggest that these variants evolve simultaneously in different countries though detected first in some while postulating that some drugs might share in their evolution and recommending that SARS CoV-2 vaccination, probably the subunit not the gene based or the inactivated ones, should be offered only to the high-risk groups after an informed personalized risk benefit ratio has been weighed.

Numerous SARS CoV-2 variants were suggested to cause a higher number of infections, worse clinical outcomes, escape of the immune system and vaccines as well as diagnostic hardships¹ and the WHO has suggested a preliminary evidence of their more rapid spread, more severe complications or evasion of previously acquired immunity [<https://www.nature.com/articles/d41586-021-01274-7>] and they were dubbed as variants of interest or concern [<https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Consequence>]. Thus, we wish to explore some potential causes that might have triggered and/or will trigger the evolution of these virulent variants using India as an example.

We have witnessed the emergence of the SARS CoV-2 B.1.617 variants first identified in India in October 2020 and later the delta B.1.617.2 variant of concern was identified in more than 80 countries as recently declared by the WHO. Notably, the Indian surge of cases and mortalities was considered of international grave concern [<https://www.nature.com/articles/d41586-021-01274-7>] especially as these variants are expected to be the dominant ones elsewhere over time [<https://www.cnn.com/2021/06/16/who-says-delta-covid-variant-has-now-spread-to-80-countries-and-it-keeps-mutating.html>].

Some authors have claimed that SARS CoV-2 B.1.617 variants have mainly evolved first in India because of lack of control on crowd-gatherings [<https://www.nature.com/articles/d41586-021-01059-y>] and others suggested that its spread might have been prevented if strictest quarantine requirements were imposed on everyone arriving from India [<https://www.nbcnews.com/news/world/u-k-records-over-10-000-covid-cases-first-time-n1271197?fbclid=IwAR1dsQzKBFuKeBiHy9aQ-olJZh4wA67YhXmRFesPMP3UctwhmRIYeSqAlc4>] we suggest these theories are least likely probabilities as many developing countries impose similar or much worse minimal control on crowd-gatherings, yet their report of SARS CoV-2 variants and more importantly their surge of COVID-19 infections and/or mortalities are much better than that of India though some of these countries share similar genetic profile. Moreover, we claim that not only the delta variant but almost all other variants have evolved simultaneously in different countries, though detected first in some and named after them.

We suggest that the prevalent use of the ineffective and mutagenic antiviral drugs; remdesivir and favipriavir, respectively ² especially in combination with the immunosuppressive dexamethasone³ are the main causes of evolution of these SARS CoV-2 variants of interest and/or concern leading to the recently encountered Indian unprecedented surge of COVID-19 induced mortality which might be repeated, in any other country, with potentially more virulent variants e.g. delta plus especially after the end of the mass vaccination programs with SARS CoV-2 vaccines⁴ unless, as we suggest, a prompt decision to discontinue remdesivir and favipiravir use in COVID-19 management is being made together with a re-evaluation of the long-term efficacy/hazards of the current SARS CoV-2 mass vaccination programs as we suggest it might reveal as one of the worst medical decisions that have been ever made and it should have been only considered to be administered to the high risk groups, probably the subunit not the gene based or the inactivated ones, after an informed personalized evaluation of the risk/benefit ratio has been undertaken⁵. Moreover, we suggest that the anticipated mutagenic antiviral drug molnupiravir⁶ would not significantly differ from favipiravir [<https://www.reuters.com/article/us-health-coronavirus-fujifilm-avigan/fujifilms-avigan-shows-no-significant-benefit-on-covid-19-mortality-study-idUSKBN2AI0SK>] but we anticipate an “announced success” in outpatient settings after the overt failure to manage the COVID-19 hospitalized patients while providing subtle excuses [<https://www.reuters.com/business/healthcare-pharmaceuticals/merck-plans-large-outpatient-trial-covid-19-pill-stops-study-hospitalized-2021-04-15/>] and unfortunately when billions of dollars are on the stake [<https://www.yahoo.com/gma/merck-signs-1-2-billion-175655042.html>], few might dare to argue that the risk benefit ratio of using molnupiravir for COVID-19 outpatient settings is totally imbalanced with more profound short (variants of interest and concern) and long (potential latent carcinogenicity) ² risks to be considered.

Finally, the need of a proper COVID-19 management protocol has been shown of paramount importance to reduce the probability of resistant strain establishment⁷ and we suggest that our immunomodulatory safe, simple, inexpensive and successful one that has been unfortunately ignored for more than one year might prove the best suitable alternative

to save lives and to minimized the evolutionary risk to develop more virulent and lethal SARS CoV-2 variants^{8 9}.

References

1. Happi AN, Ugwu CA, Happi CT. Tracking the emergence of new SARS-CoV-2 variants in South Africa. *Nature Medicine* 2021;27:372-3.
2. Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. *SN Compr Clin Med* 2021;3:919-23.
3. Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. *Infect Dis Clin North Am* 2010;24:413-37.
4. Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for concern? *The Lancet Respiratory Medicine* 2021;9:333-5.
5. Autoimmunity and Antibody Dependent COVID-19 Enhancement of SARS CoV-2 Vaccination: A Global Human Right to Know then Decide. *Authorea (Preprint)* 2021. DOI: 10.22541/au.162126651.13093279/v3.
6. Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. *Journal of Biological Chemistry*.
7. Rella SA, Kulikova YA, Dermitzakis ET, Kondrashov FA. SARS-CoV-2 transmission, vaccination rate and the fate of resistant strains. *medRxiv* 2021:2021.02.08.21251383.
8. Kelleni MT. NSAIDs/Nitazoxanide/Azithromycin Repurposed for COVID-19: Potential Mitigation of the Cytokine Storm Interleukin-6 Amplifier via Immunomodulatory Effects. *Expert Review of Anti-infective Therapy* 2021;DOI: 10.1080/14787210.2021.1939683.
9. Kelleni M. NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adults, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Prospective Observational Study and Case-Series. *Authorea (Preprint)* DOI: 10.22541/au.162126601.15715282/v2.